Who are Cytarabine's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Hepsera, Gemzar, VALACYCLOVIR, prophylactic Valganciclovir, Fludarabine (Bayer), Angelicin.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/cytarabine.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-13 · How we verify

Cytarabine — Competitive Intelligence Brief

Cytarabine (Cytarabine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimetabolite. Area: Oncology.

marketed Antimetabolite DNA polymerase Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Cytarabine — Nippon Shinyaku Co., Ltd.. Cytarabine inhibits DNA polymerase and incorporates into DNA/RNA, killing cells in S-phase.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Cytarabine TARGET	Cytarabine	Nippon Shinyaku Co., Ltd.	marketed	Antimetabolite	DNA polymerase	1969-01-01
Hepsera	ADEFOVIR DIPIVOXIL	Gilead Sciences	marketed	Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor	DNA polymerase subunit gamma-1	2002-01-01
Gemzar	gemcitabine	Accord Hlthcare	marketed	Nucleoside Metabolic Inhibitor	DNA polymerase (alpha/delta/epsilon)	1996-01-01
VALACYCLOVIR	VALACYCLOVIR		marketed	Nucleoside analogue	Viral DNA polymerase	1995-01-01
prophylactic Valganciclovir	prophylactic Valganciclovir	Rabin Medical Center	marketed	Nucleoside analog antiviral	CMV DNA polymerase
Fludarabine (Bayer)	Fludarabine (Bayer)	Chinese PLA General Hospital	marketed	Purine analog antimetabolite	Ribonucleotide reductase, DNA polymerase
Angelicin	sitosterol		marketed	sitosterol	DNA polymerase beta, Amine oxidase [flavin-containing] A, Amine oxidase [flavin-containing] B

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimetabolite class)

Grupo Espanol Multidisciplinario del Cancer Digestivo · 2 drugs in this class
NRG Oncology · 2 drugs in this class
Bristol-Myers Squibb · 1 drug in this class
EMD Serono Research & Development Institute, Inc. · 1 drug in this class
GERCOR - Multidisciplinary Oncology Cooperative Group · 1 drug in this class
Hoffmann-La Roche · 1 drug in this class
Centre Oscar Lambret · 1 drug in this class
Iwate Medical University · 1 drug in this class
Janssen Research & Development, LLC · 1 drug in this class
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Cytarabine — Competitive Intelligence Brief. https://druglandscape.com/ci/cytarabine. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab